GlaxoSmithKline taps Baltimore’s Insilico for AI-based drug discovery GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter’s artificial intelligence technology can aid in the drug discovery process. The duo kept mum on the details but said the agreement comes after Baltimore-based Insilico ...
Find MorePD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer. DelveIns...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!